Dinutuximab beta (Qarziba®), a monoclonal antibody, is indicated to treat high-risk neuroblastoma in patients aged ≥ 12 months in the first-line setting subsequent to front-line treatment with induction chemotherapy, myeloablative therapy and stem cell transplantation (SCT), as well as in the relapsed/refractory setting. It targets disialoganglioside 2, which is highly expressed on neuroblastoma cells. Unlike dinutuximab, which is produced using mouse SP2/0 cells, dinutuximab beta is produced using the more widely used Chinese hamster ovary cells. In both the first-line and relapsed/refractory settings, treatment with dinutuximab beta achieves objective clinical responses in patients with high-risk neuroblastoma. Following standard front-line treatment, survival rates were higher in dinutuximab beta recipients than in historical controls treated in the pre-immunotherapy era. Appropriate measures should be taken to manage toxicities (e.g. neuropathic pain, pyrexia and hypersensitivity reactions) associated with dinutuximab beta treatment. The continuous, 10-day infusion regimen appears to be associated with less toxicity than the once-daily infusion on 5 consecutive days.
Drugs & Therapy Perspectives – Springer Journals
Published: May 23, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera